The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial
Abstract
Background— Single-bolus intracoronary administration of fibroblast growth factor-2 (FGF2) improved symptoms and myocardial function in a phase I, open-label trial in patients with coronary artery disease. We conducted the FGF Initiating RevaScularization Trial (FIRST) to evaluate further the efficacy and safety of recombinant FGF2 (rFGF2). Methods and Results— FIRST is a multicenter, randomized, double-blind, placebo-controlled trial of a single intracoronary infusion of rFGF2 at 0, 0.3, 3, or 30 μg/kg (n=337 patients). Efficacy was evaluated at 90 and 180 days by exercise tolerance test, myocardial nuclear perfusion imaging, Seattle Angina Questionnaire, and Short-Form 36 questionnaire. Exercise tolerance was increased at 90 days in all groups and was not significantly different between placebo and FGF-treated groups. rFGF2 reduced angina symptoms as measured by the angina frequency score of the Seattle Angina Questionnaire (overall P =0.035) and the physical component summary scale of the Short-Form 36 (pairwise P =0.033, all FGF groups versus placebo). These differences were more pronounced in highly symptomatic patients (baseline angina frequency score ≤40 or Canadian Cardiovascular Society score of III or IV). None of the differences were significant at 180 days because of continued improvement in the placebo group. Adverse events were similar across all groups, except for hypotension, which occurred with higher frequency in the 30-μg/kg rFGF2 group. Conclusions— A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Kim, R. J., Wu, E., Rafael, A., Chen, E.-L., Parker, M. A., Simonetti, O., Klocke, F. J., Bonow, R. O., & Judd, R. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432003 · Cited by 3,306
Spertus, J. A., Winder, J. A., Dewhurst, T. A., Deyo, R. A., Prodzinski, J., McDonnell, M., & Fihn, S. D. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00397-9 · Cited by 1,385
Losordo, D. W., Vale, P. R., Symes, J. F., Dunnington, C. H., Esakof, D. D., Maysky, M., Ashare, A. B., Lathi, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.98.25.2800 · Cited by 987
Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., & Tarnawski, A. S. (1999) · Nature Medicine · doi:10.1038/70995 · Cited by 827
Parisi, A. F., Folland, E. D., & Hartigan, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260102 · Cited by 736
Schwitter, J., Nanz, D., Kneifel, S., Bertschinger, K., Büchi, M., Knüsel, P. R., Marincek, B., Lüscher, T. F., & von Schulthess, G. K. (2001) · Circulation · doi:10.1161/01.cir.103.18.2230 · Cited by 663
Rosengart, T. K., Lee, L. Y., Patel, S. R., Sanborn, T. A., Parikh, M., Bergman, G. W., Hachamovitch, R., Szulc, M., Kligfield, P. D., Okin, P. M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.5.468 · Cited by 656
Fibroblast Growth Factors as Multifunctional Signaling Factors
Szebenyi, G., & Fallon, J. F. (1998) · International Review of Cytology · doi:10.1016/s0074-7696(08)60149-7 · Cited by 484
Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus: An Expert Panel Summary
Simons, M., Bonow, R. O., Chronos, N. A., Cohen, D. J., Giordano, F. J., Hammond, H. K., Laham, R. J., Li, W., Pike, M., Sellke, F. W., et al. (2000) · Circulation · doi:10.1161/01.cir.102.11.e73 · Cited by 459
Self-citation
Cited by
Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., Bovenkerk, J. E., Pell, C. L., Johnstone, B. H., Considine, R. V., & March, K. L. (2004) · Circulation · doi:10.1161/01.cir.0000121425.42966.f1 · Cited by 2,269
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
“However, in the FGF Initiating RevaScularization Trial (FIRST), FGF2 treatment conferred some benefit in the first few months, but these improvements were not sustained, whereas continued improvement was seen in the placebo grou”
Kinnaird, T., Stabile, E., Burnett, M. S., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004) · Circulation Research · doi:10.1161/01.res.0000118601.37875.ac · Cited by 1,415
Lee, K., Silva, E. A., & Mooney, D. J. (2011) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0223 · Cited by 1,386
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
A review on coronary artery disease, its risk factors, and therapeutics
Malakar, A. K., Choudhury, D., Halder, B., Paul, P., Uddin, A., & Chakraborty, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28350 · Cited by 1,141
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025
Self-citationFGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Cao, R., Bråkenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., Wahlberg, E., Leboulch, P., & Cao, Y. (2003) · Nature Medicine · doi:10.1038/nm848 · Cited by 721
“A recent FGF-2–based random, double-blind, controlled trial of FGF-2 in the treatment of coronary artery disease showed trends toward short-term, but not long-term, symptomatic improvemen”
BackgroundLederman, R. J., Mendelsohn, F. O., Anderson, R. D., Saucedo, J. F., Tenaglia, A. N., Hermiller, J. B., Hillegass, W. B., Rocha-Singh, K., Moon, T. E., Whitehouse, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08937-7 · Cited by 511
Self-citationVascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Timmers, L., Lim, S. K., Hoefer, I. E., Arslan, F., Lai, R. C., van Oorschot, A. A. M., Goumans, M. J., Strijder, C., Sze, S. K., Choo, A., et al. (2011) · Stem Cell Research · doi:10.1016/j.scr.2011.01.001 · Cited by 430
Controlled Growth Factor Delivery for Tissue Engineering
Tayalia, P., & Mooney, D. J. (2009) · Advanced Materials · doi:10.1002/adma.200900241 · Cited by 430
Fuchs, S., Satler, L. F., Kornowski, R., Okubagzi, P., Weisz, G., Baffour, R., Waksman, R., Weissman, N. J., Cerqueira, M., Leon, M. B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00328-0 · Cited by 419
Therapeutic approaches for cardiac regeneration and repair
Hashimoto, H., Olson, E. N., & Bassel-Duby, R. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0036-6 · Cited by 415
Angiogenesis: Where Do We Stand Now?
Simons, M. (2005) · Circulation · doi:10.1161/01.cir.0000159345.00591.8f · Cited by 411
Self-citationGene transfer as a tool to induce therapeutic vascular growth
Ylä-Herttuala, S., & Alitalo, K. (2003) · Nature Medicine · doi:10.1038/nm0603-694 · Cited by 404
Angiogenesis after acute myocardial infarction
Wu, X., Reboll, M. R., Korf-Klingebiel, M., & Wollert, K. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa287 · Cited by 379
Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines
Losordo, D. W., & Dimmeler, S. (2004) · Circulation · doi:10.1161/01.cir.0000128595.79378.fa · Cited by 357
Moon, M. H., Kim, S. Y., Kim, Y. J., Kim, S. J., Lee, J. B., Bae, Y. C., Sung, S. M., & Jung, J. S. (2006) · Cellular Physiology and Biochemistry · doi:10.1159/000094140 · Cited by 331
Therapeutic angiogenesis in cardiovascular disease
Simons, M., & Ware, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1226 · Cited by 325
Self-citationTherapeutic angiogenesis for critical limb ischaemia
Annex, B. H. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.70 · Cited by 298
Self-citationGrines, C. L., Watkins, M. W., Mahmarian, J. J., Iskandrian, A. E., Rade, J. J., Marrott, P., Pratt, C., & Kleiman, N. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00988-4 · Cited by 289
Self-citationStewart, D. J., Hilton, J. D., Arnold, J. M. O., Gregoire, J., Rivard, A., Archer, S. L., Charbonneau, F., Cohen, E., Curtis, M., Buller, C. E., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302802 · Cited by 281
Arteriogenesis The Development and Growth of Collateral Arteries
Helisch, A., & Schaper, W. K. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800173 · Cited by 279
Kano, M. R., Morishita, Y., Iwata, C., Iwasaka, S., Watabe, T., Ouchi, Y., Miyazono, K., & Miyazawa, K. (2005) · Journal of Cell Science · doi:10.1242/jcs.02483 · Cited by 277
Stewart, D. J., Kutryk, M. J., Fitchett, D., Freeman, M., Camack, N., Su, Y., Siega, A. D., Bilodeau, L., Burton, J. R., Proulx, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.70 · Cited by 268
The role of fibroblast growth factors in vascular development
Javerzat, S., Auguste, P., & Bikfalvi, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02394-8 · Cited by 266
Kinnaird, T., Stabile, E., Burnett, M. S., & Epstein, S. E. (2004) · Circulation Research · doi:10.1161/01.res.0000137878.26174.66 · Cited by 265
Postischemic Revascularization: From Cellular and Molecular Mechanisms to Clinical Applications
Silvestre, J.-S., Smadja, D. M., & Lévy, B. I. (2013) · Physiological Reviews · doi:10.1152/physrev.00006.2013 · Cited by 255
Garbern, J. C., Minami, E., Stayton, P. S., & Murry, C. E. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.075 · Cited by 252
Targeted Delivery of Nanoparticles to Ischemic Muscle for Imaging and Therapeutic Angiogenesis
Kim, J., Cao, L., Shvartsman, D., Silva, E. A., & Mooney, D. J. (2011) · Nano Letters · doi:10.1021/nl103812a · Cited by 150
Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles
Evers, M. J. W., Du, W., Yang, Q., Kooijmans, S. A. A., Vink, A., van Steenbergen, M., Vader, P., de Jager, S. C. A., Fuchs, S. A., Mastrobattista, E., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.027 · Cited by 113
Lu, H., Xu, X., Zhang, M., Cao, R., Bråkenhielm, E., Li, C., Lin, H., Yao, G., Sun, H., Qi, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704966104 · Cited by 107
Metadata
- Authors
- Simons, M., Annex, B. H., Laham, R. J., Kleiman, N., Henry, T., Dauerman, H., Udelson, J. E., Gervino, E. V., Pike, M., Whitehouse, M. J., Moon, T., & Chronos, N. A.
- Venue
- Circulation
- Published
- 2002-02-19
- Volume
- 105
- Issue
- 7
- Pages
- 788-793
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2138369468
- Cited by
- 645
- References
- 26
- FWCI
- 50.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.